Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care

Aziz Nazha, Mikkael A. Sekeres, Rami Komrokji, David P. Steensma, Hagop Kantarjian, Gail Roboz, Pierre Fenaux, Thomas Prebet, Nozar Azarnia, Patrick S. Zbyszewski, Steven M. Fruchtman, Valeria Santini, Lewis R. Silverman, Uwe Platzbecker, Guillermo Garcia-Manero

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care'. Together they form a unique fingerprint.